INTENSITY THERAPEUTICS INC (INTS) Stock Price, Quote, News and Overview
NASDAQ:INTS - Nasdaq - US45828J1034 - Common Stock - Currency: USD
INTS Quote, Performance and Key Statistics
NASDAQ:INTS (4/22/2025, 3:30:54 PM)
1.91
-0.03 (-1.55%)
The current stock price of INTS is 1.91 USD. In the past month the price decreased by -3%. In the past year, price decreased by -50.57%.
INTS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.18 | 307.57B | ||
| AMGN | AMGEN INC | 14.05 | 149.75B | ||
| GILD | GILEAD SCIENCES INC | 22.88 | 131.49B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1691.52 | 126.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.84 | 64.05B | ||
| ARGX | ARGENX SE - ADR | 322.58 | 36.64B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.79B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.26B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.25B | ||
| NTRA | NATERA INC | N/A | 19.56B | ||
| BIIB | BIOGEN INC | 7.22 | 17.41B |
Related stock screener links
About INTS
Company Profile
Intensity Therapeutics, Inc. operates as biotechnology company which develops novel immune-based therapeutic products for cancer treatment. The company is headquartered in Shelton, Connecticut and currently employs 5 full-time employees. The company went IPO on 2023-06-30. The firm is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead investigational product candidate, INT230-6, is designed for direct intratumoral injection. Its INT230-6 is primarily comprised of three components: cisplatin, vinblastine sulfate and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of Phase III open-label, randomized study testing the superiority of INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, and Phase II/III clinical study in metastatic triple negative breast cancer.
Company Info
INTENSITY THERAPEUTICS INC
1 Enterprise Drive, Suite 430
Shelton CONNECTICUT US
Employees: 6
Company Website: https://www.intensitytherapeutics.com
Investor Relations: https://ir.intensitytherapeutics.com/
Phone: 12032217381
INTENSITY THERAPEUTICS INC / INTS FAQ
What is the stock price of INTENSITY THERAPEUTICS INC today?
The current stock price of INTS is 1.91 USD. The price decreased by -1.55% in the last trading session.
What is the ticker symbol for INTENSITY THERAPEUTICS INC stock?
The exchange symbol of INTENSITY THERAPEUTICS INC is INTS and it is listed on the Nasdaq exchange.
On which exchange is INTS stock listed?
INTS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for INTENSITY THERAPEUTICS INC stock?
11 analysts have analysed INTS and the average price target is 9.49 USD. This implies a price increase of 396.65% is expected in the next year compared to the current price of 1.91. Check the INTENSITY THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is INTENSITY THERAPEUTICS INC worth?
INTENSITY THERAPEUTICS INC (INTS) has a market capitalization of 28.99M USD. This makes INTS a Nano Cap stock.
How many employees does INTENSITY THERAPEUTICS INC have?
INTENSITY THERAPEUTICS INC (INTS) currently has 6 employees.
What are the support and resistance levels for INTENSITY THERAPEUTICS INC (INTS) stock?
INTENSITY THERAPEUTICS INC (INTS) has a support level at 1.93 and a resistance level at 1.99. Check the full technical report for a detailed analysis of INTS support and resistance levels.
Should I buy INTENSITY THERAPEUTICS INC (INTS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of INTS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of INTS, evaluating the profitability, health, valuation and growth aspects
- INTENSITY THERAPEUTICS INC (INTS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INTENSITY THERAPEUTICS INC (INTS) Sales and EPS estimates to see what analysts future expectations are.
- INTENSITY THERAPEUTICS INC (INTS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INTENSITY THERAPEUTICS INC (INTS) Insider and Institutional Ownership to learn about the owners and their transactions.
- INTENSITY THERAPEUTICS INC (INTS) Stock Chart to make your own analysis
- INTENSITY THERAPEUTICS INC (INTS) Latest news and press-releases to stay up to date.
Does INTENSITY THERAPEUTICS INC (INTS) stock pay dividends?
INTS does not pay a dividend.
When does INTENSITY THERAPEUTICS INC (INTS) report earnings?
INTENSITY THERAPEUTICS INC (INTS) will report earnings on 2025-05-08.
What is the Price/Earnings (PE) ratio of INTENSITY THERAPEUTICS INC (INTS)?
INTENSITY THERAPEUTICS INC (INTS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.17).
What is the Short Interest ratio of INTENSITY THERAPEUTICS INC (INTS) stock?
The outstanding short interest for INTENSITY THERAPEUTICS INC (INTS) is 0.58% of its float. Check the ownership tab for more information on the INTS short interest.
INTS Technical Analysis
INTS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to INTS. While INTS seems to be doing ok healthwise, there are quite some concerns on its profitability.
INTS Financial Highlights
Over the last trailing twelve months INTS reported a non-GAAP Earnings per Share(EPS) of -1.17. The EPS decreased by -21.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -340.12% | ||
| ROE | -557.51% | ||
| Debt/Equity | 0 |
INTS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to INTS. The Buy consensus is the average rating of analysts ratings from 11 analysts.